Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

BACKGROUND: Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the rate of relapse and disability progression in relapsing-remitting multi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Alroughani, Raed A, Aref, Hany M, Bohlega, Saeed A, Dahdaleh, Maurice P, Feki, Imed, Al Jumah, Mohammed A, Al-Kawi, Muhammad Z, Koussa, Salam F, Sahraian, Mohamad A, Alsharoqi, Isa A, Yamout, Bassem I
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2014
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3927624/
https://ncbi.nlm.nih.gov/pubmed/24521176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-14-27
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky